These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38444047)

  • 21. In Silico and In Vitro Evaluations of Fluorophoric Thiazolo-[2,3-b]quinazolinones as Anti-cancer Agents Targeting EGFR-TKD.
    Mir SA; Dash GC; Meher RK; Mohanta PP; Chopdar KS; Mohapatra PK; Baitharu I; Behera AK; Raval MK; Nayak B
    Appl Biochem Biotechnol; 2022 Oct; 194(10):4292-4318. PubMed ID: 35366187
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New benzothienopyrimidine derivatives as dual EGFR/ARO inhibitors: Design, synthesis, and their cytotoxic effect on MCF-7 breast cancer cell line.
    Sobh EA; Khalil NA; Faggal SI; Hassan MSA
    Drug Dev Res; 2022 Aug; 83(5):1075-1096. PubMed ID: 35286757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis, molecular docking, and anticancer activity of benzoxazole derivatives as VEGFR-2 inhibitors.
    El-Helby AA; Sakr H; Eissa IH; Abulkhair H; Al-Karmalawy AA; El-Adl K
    Arch Pharm (Weinheim); 2019 Oct; 352(10):e1900113. PubMed ID: 31448458
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, Synthesis, Cytotoxic Evaluation and Molecular Docking of New Fluoroquinazolinones as Potent Anticancer Agents with Dual EGFR Kinase and Tubulin Polymerization Inhibitory Effects.
    Zayed MF; Ahmed S; Ihmaid S; Ahmed HEA; Rateb HS; Ibrahim SRM
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29891789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile.
    Mghwary AE; Gedawy EM; Kamal AM; Abuel-Maaty SM
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):838-852. PubMed ID: 30919701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
    Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
    Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New oxadiazoles with selective-COX-2 and EGFR dual inhibitory activity: Design, synthesis, cytotoxicity evaluation and in silico studies.
    El-Sayed NA; Nour MS; Salem MA; Arafa RK
    Eur J Med Chem; 2019 Dec; 183():111693. PubMed ID: 31539778
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New pyrimidine and pyrazole-based compounds as potential EGFR inhibitors: Synthesis, anticancer, antimicrobial evaluation and computational studies.
    Othman IMM; Alamshany ZM; Tashkandi NY; Gad-Elkareem MAM; Anwar MM; Nossier ES
    Bioorg Chem; 2021 Sep; 114():105078. PubMed ID: 34161878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, Synthesis, and Antiproliferative Activity of New 5-Chloro-indole-2-carboxylate and Pyrrolo[3,4-
    Al-Wahaibi LH; Mohammed AF; Abdelrahman MH; Trembleau L; Youssif BGM
    Molecules; 2023 Jan; 28(3):. PubMed ID: 36770936
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Computational Studies of bis-2-Oxoindoline Succinohydrazides and their In Vitro Cytotoxicity.
    Jarapula R; Badavath VN; Rekulapally S; Manda S
    Curr Comput Aided Drug Des; 2020; 16(3):270-280. PubMed ID: 30652647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Computational Design, Synthesis, and Bioevaluation of 2-(Pyrimidin-4-yl)oxazole-4-carboxamide Derivatives: Dual Inhibition of EGFR
    Raghunath Khedkar N; Sindkhedkar M; Joseph A
    Bioorg Chem; 2024 Feb; 143():107027. PubMed ID: 38096682
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis and molecular docking of new [1,2,4] triazolo[4,3-a]quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase.
    Alsaif NA; Elwan A; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari AF; Albassam H; Mahdy HA; Taghour MS
    Mol Divers; 2022 Aug; 26(4):1915-1932. PubMed ID: 34460053
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis, anticancer and apoptosis-inducing activities of quinazoline-isatin conjugates: epidermal growth factor receptor-tyrosine kinase assay and molecular docking studies.
    El-Azab AS; Al-Dhfyan A; Abdel-Aziz AA; Abou-Zeid LA; Alkahtani HM; Al-Obaid AM; Al-Gendy MA
    J Enzyme Inhib Med Chem; 2017 Dec; 32(1):935-944. PubMed ID: 28718672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives.
    Mourad AAE; Farouk NA; El-Sayed EH; Mahdy ARE
    Life Sci; 2021 Jul; 277():119531. PubMed ID: 33887348
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis, in vitro anticancer activity and in silico studies of certain isoxazole-based carboxamides, ureates, and hydrazones as potential inhibitors of VEGFR2.
    Abou-Seri SM; Eissa AAM; Behery MGM; Omar FA
    Bioorg Chem; 2021 Nov; 116():105334. PubMed ID: 34534755
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New bis([1,2,4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and anticancer evaluation.
    Alanazi MM; Mahdy HA; Alsaif NA; Obaidullah AJ; Alkahtani HM; Al-Mehizia AA; Alsubaie SM; Dahab MA; Eissa IH
    Bioorg Chem; 2021 Jul; 112():104949. PubMed ID: 34023640
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of novel rigid analogs of 2-naphthol with potent anticancer activity through multi-target topoisomerase I & II and tyrosine kinase receptor EGFR & VEGFR-2 inhibition mechanism.
    El-Mawgoud HKA; Fouda AM; El-Nassag MAA; Elhenawy AA; Alshahrani MY; El-Agrody AM
    Chem Biol Interact; 2022 Mar; 355():109838. PubMed ID: 35123995
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis, cytotoxic evaluation, and molecular docking studies of novel quinazoline derivatives with benzenesulfonamide and anilide tails: Dual inhibitors of EGFR/HER2.
    Alkahtani HM; Abdalla AN; Obaidullah AJ; Alanazi MM; Almehizia AA; Alanazi MG; Ahmed AY; Alwassil OI; Darwish HW; Abdel-Aziz AA; El-Azab AS
    Bioorg Chem; 2020 Jan; 95():103461. PubMed ID: 31838290
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemical Characterization,
    Ansari JA; Ahmad MK; Fatima N; Azad I; Mahdi AA; Satyanarayan GNV; Ahmad N
    Anticancer Agents Med Chem; 2022; 22(20):3416-3437. PubMed ID: 35125087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In Vitro and In Silico Evaluation of Anticancer Activity of New Indole-Based 1,3,4-Oxadiazoles as EGFR and COX-2 Inhibitors.
    Sever B; Altıntop MD; Özdemir A; Akalın Çiftçi G; Ellakwa DE; Tateishi H; Radwan MO; Ibrahim MAA; Otsuka M; Fujita M; Ciftci HI; Ali TFS
    Molecules; 2020 Nov; 25(21):. PubMed ID: 33171861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.